Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA.
We have 9 contacts in our database, out of which 56% are decision makers. The distribution of leads are as follows:
In October, 2019 inva.com's total website visitor was 5409, None. Some key metrics are Average time spent on site is 0 minutes, Bounce Rate is 0% and average page per visit is 2 respectively.
We Verified inva.com server for email deliverability.
Microsoft today declared that it has acquired Affirmed Networks, an organization that specializes...